Literature DB >> 27635291

Comparison of intraoperative and postoperative complications based on ASA risks in patients who underwent percutaneous nephrolithotomy.

Hüseyin Buğra Karakaş1, İzzet Çiçekbilek2, Adem Tok2, Tamer Alışkan2, Bülent Akduman2.   

Abstract

OBJECTIVE: In this study we aimed to evaluate intraoperative and postoperative complications which developed according to pre-operative American Society of Anesthesiologists (ASA) risk criteria in patients who had undergone percutaneous nephrolithotomy (PNL).
MATERIAL AND METHODS: Five hundred and sixty patients who had undergone PNL between 2002 and 2014 were included in the study. Patients operated on the ipsilateral kidney, those with solitary kidney or the cases who had previously undergone more than one access were excluded from this study. Preoperative anesthesia risks were determined according to preoperative classification developed by ASA. Postoperative complications were evaluated using Clavien Complication Grading Scale.
RESULTS: The mean age of the cases was 47±14 years. The 57% (n=319) of the cases were male, 241 (43%) of them were female. The average indwell time of nephrostomy catheter was 2.88±1.00 (1-8), and length of hospital stay was 4.91±1.54 (2-17) days. When the cases were assessed according to ASA risk groups, intraoperative complications were observed in 9 (5.5%) ASA I, 27 (8.6%) ASA II, and 18 (22%) ASA III patients and and distribution of the patients was statistically significant (p<0.001). When intraoperative complications were evaluated one by one, intraoperative hypotension developed in ASA I (n=3; 1.8%), ASA II (n=20; 6.4%) and ASA III (n=11; 13.4%) risk groups and this distribution (p=0.002) of patients was statistically significant. When assessed according to Clavien Postoperative Scale, postoperative complications developed (p=0.053) in ASAI (n=24; 14.7%), ASA II (n=27, 8.6%) and ASA III (n=13; 15.9%) risk groups, and this distribution of the patients was not statistically significant. In postoperative complications, Grade 3a complications developed in ASA I (n=12; 7.4%), ASA II (n=19; 6%) and ASA III (n=8; 9.8%) risk groups and this distribution was not seen to be statistically significant (p=0.485).
CONCLUSION: A statistically significant difference observed regarding intraoperative complications in the groups formed according to ASA risk criteria, on Clavien Grading scale no statistically significant difference was observed as for postoperative complications. In this context, we considered that ASA risks are major risk factors for PNL operations in terms of intraoperative complications.

Entities:  

Keywords:  ASA; Clavien; percutaneous nephrolithotomy; postoperative complications

Year:  2016        PMID: 27635291      PMCID: PMC5012443          DOI: 10.5152/tud.2016.78545

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  22 in total

Review 1.  Complications in percutaneous nephrolithotomy.

Authors:  Maurice Stephan Michel; Lutz Trojan; Jens Jochen Rassweiler
Journal:  Eur Urol       Date:  2006-10-25       Impact factor: 20.096

2.  The percutaneous nephrolithotomy global study: classification of complications.

Authors:  Gaston Labate; Pranjal Modi; Anthony Timoney; Luigi Cormio; Xiaochun Zhang; Michael Louie; Magnus Grabe; Jean Rosette On Behalf Of The Croes Pcnl Study Group
Journal:  J Endourol       Date:  2011-07-13       Impact factor: 2.942

3.  The ASA classification and peri-operative risk.

Authors:  Jo Fitz-Henry
Journal:  Ann R Coll Surg Engl       Date:  2011-04       Impact factor: 1.891

4.  ASA classification and perioperative variables as predictors of postoperative outcome.

Authors:  U Wolters; T Wolf; H Stützer; T Schröder
Journal:  Br J Anaesth       Date:  1996-08       Impact factor: 9.166

5.  Impact of case volumes on the outcomes of percutaneous nephrolithotomy.

Authors:  Dedan Opondo; Ahmet Tefekli; Tarik Esen; Gaston Labate; Kandasami Sangam; Antonello De Lisa; Hemendra Shah; Jean de la Rosette
Journal:  Eur Urol       Date:  2012-03-16       Impact factor: 20.096

Review 6.  Standardization of patient outcomes reporting in percutaneous nephrolithotomy.

Authors:  Dedan Opondo; Stavros Gravas; Andrian Joyce; Margaret Pearle; Tadashi Matsuda; Ying-Hao Sun; Dean Assimos; John Denstedt; Jean de la Rosette
Journal:  J Endourol       Date:  2014-04-16       Impact factor: 2.942

7.  Risk Factors for Postoperative Complications of Percutaneous Nephrolithotomy at a Tertiary Referral Center.

Authors:  Daniel Olvera-Posada; Thomas Tailly; Husain Alenezi; Philippe D Violette; Linda Nott; John D Denstedt; Hassan Razvi
Journal:  J Urol       Date:  2015-07-02       Impact factor: 7.450

8.  Prediction of morbidity and mortality after percutaneous nephrolithotomy by using the Charlson Comorbidity Index.

Authors:  Ali Unsal; Berkan Resorlu; Ali Fuat Atmaca; Akif Diri; Hasan Nedim Goksel Goktug; Ceren Eda Can; Bahri Gok; Can Tuygun; Cankon Germiyonoglu
Journal:  Urology       Date:  2012-01       Impact factor: 2.649

9.  Percutaneous nephrolithotomy can be safely performed in the high-risk patient.

Authors:  Sutchin R Patel; George E Haleblian; Gyan Pareek
Journal:  Urology       Date:  2009-09-25       Impact factor: 2.649

10.  Comparison of percutaneous nephrolithotomy under spinal versus general anesthesia: a randomized clinical trial.

Authors:  Akbar Nouralizadeh; Seyed Amir Mohsen Ziaee; Seyed Hossein Hosseini Sharifi; Abbas Basiri; Ali Tabibi; Farzaneh Sharifiaghdas; Hossein Kilani; Babak Gharaei; Fatemeh Roodneshin; Mohammad Hossein Soltani
Journal:  J Endourol       Date:  2013-07-13       Impact factor: 2.942

View more
  2 in total

1.  [Massive bleeding of the urogenital tract].

Authors:  C-A J von Klot; R Fricke; M A Kuczyk; H Tezval
Journal:  Internist (Berl)       Date:  2017-03       Impact factor: 0.743

2.  Percutaneous Nephrolithotomy with Amplatz and Alken Dilators: An Eight-Year Single Tertiary Care Centre Experience.

Authors:  Piotr Bryniarski; Paweł Stelmach; Piotr Taborowski; Paweł Rajwa; Mateusz Adamkiewicz; Marcin Życzkowski; Andrzej Paradysz
Journal:  Med Sci Monit       Date:  2016-12-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.